CIK 0001437402 · Large accelerated filer
ARDELYX, INC.
Sign in to watch- Ticker
- ARDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 510-745-7047
- Business address
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Former names
- NTERYX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $486,197
- in 8 filings
Net −$486,197. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- RAAB MICHAEL −$226K President & CEO sold 3% of stake
- Bishop John E −$76K See Remarks sold 6% of stake
- Brady James Parker −$58K Chief Human Resources Officer sold 6% of stake
- Williams Laura A −$41K Chief Patient Officer sold 3% of stake
- Foster Eric Duane −$33K Chief Commercial Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-20 | Foster Eric Duane Chief Commercial Officer | Sale | −2,507 | $4.08 | $10K | 316,806 |
| 2025-05-15 | MOTT DAVID M Director | Purchase | +100,000 | $3.29 | $329K | 2,496,871 |
| 2025-05-02 | MOTT DAVID M Director | Purchase | +381,377 | $4.22 | $1.6M | 2,396,871 |
| 2025-05-02 | RAAB MICHAEL President & CEO | Option exercise 10b5-1 | +20,833 | $0.99 | $21K | 1,636,420 |
| 2025-05-02 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −41,666 | $4.25 | $177K | 1,594,754 |
| 2025-05-02 | RAAB MICHAEL President & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,833 | 415,834 | ||
| 2025-04-28 | Parsey Merdad Director | Grant or award | +42,056 | 42,056 | ||
| 2025-04-28 | Parsey Merdad Director | Grant or award · Stock Option (Right to Buy) | +64,457 | 64,457 | ||
| 2025-04-04 | RAAB MICHAEL President & CEO | Option exercise 10b5-1 | +20,833 | $0.99 | $21K | 1,657,253 |
| 2025-04-04 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −41,666 | $4.59 | $191K | 1,615,587 |
| 2025-04-04 | RAAB MICHAEL President & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,833 | 436,667 | ||
| 2025-03-07 | RAAB MICHAEL President & CEO | Option exercise 10b5-1 | +20,834 | $0.99 | $21K | 1,676,806 |
| 2025-03-07 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −41,668 | $5.36 | $223K | 1,635,138 |
| 2025-03-07 | RAAB MICHAEL President & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,834 | 457,500 | ||
| 2025-02-25 | Williams Laura A Chief Medical Officer | Grant or award | +105,200 | 409,004 | ||
| 2025-02-25 | Williams Laura A Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +157,700 | 157,700 | ||
| 2025-02-25 | Renz Justin A Chief Financial Officer | Grant or award | +136,680 | 422,648 | ||
| 2025-02-25 | Renz Justin A Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +205,019 | 205,019 | ||
| 2025-02-25 | RAAB MICHAEL President & CEO | Grant or award | +570,217 | 1,655,972 | ||
| 2025-02-25 | RAAB MICHAEL President & CEO | Grant or award · Stock Option (Right to Buy) | +855,326 | 855,326 |
Page 9 of 11 · 206 trades